Advertisement
Advertisement
ADPT
Adaptive Biotechnologies Corporation Common Stock
26.64
USDSponsored
-1.53
-5.43%
Oct 30, 15:59 UTC -4
Closed
After-Market
26.61
-0.03
-0.09%
Adaptive Biotechnologies Corporation Common Stock (ADPT) Earnings
ADPT Earnings Reports
Positive Surprise Ratio
ADPT beat 24 of 29 last estimates.
83%
Next Report
In 3 Days
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$73.03M
/-$0.09
Implied change from Q2 26 (Revenue/ EPS)
+2.07%
/-10.00%
Implied change from Q3 25 (Revenue/ EPS)
-22.28%
/-250.00%
Adaptive Biotechnologies Corporation Common Stock earnings per share and revenue
On Jul 29, 2026, ADPT reported earnings of -0.10 USD per share (EPS) for Q2 26, beating the estimate of -0.13 USD, resulting in a 26.69% surprise. Revenue reached 71.55 million, compared to an expected 67.20 million, with a 6.47% difference. The market reacted with a +7.18% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 73.03 million USD, implying an decrease of -10.00% EPS, and increase of 2.07% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
AstraZeneca PLC
Report Date
Oct 30, 2026 For Q3 26
Estimate
$2.66
Actual
$2.79
Surprise
+4.56%
Gilead Sciences Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.24
Actual
$2.54
Surprise
+13.66%
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.47
Actual
$20.07
Surprise
+21.79%
Illumina Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.38
Actual
$1.44
Surprise
+4.18%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
FAQ
What were Adaptive Biotechnologies Corporation Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Adaptive Biotechnologies Corporation Common Stock reported EPS of -$0.10, beating estimates by 26.69%, and revenue of $71.55M, 6.47% above expectations.
How did the market react to Adaptive Biotechnologies Corporation Common Stock's Q2 2026 earnings?
The stock price moved up 7.18%, changed from $22.56 before the earnings release to $24.18 the day after.
When is Adaptive Biotechnologies Corporation Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Adaptive Biotechnologies Corporation Common Stock's next earnings report?
Based on 10
analysts, Adaptive Biotechnologies Corporation Common Stock is expected to report EPS of -$0.09 and revenue of $73.03M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.